Nurix Therapeutics (NRIX) Earnings Analysis

Nurix Therapeutics (NRIX) next reports earnings on 2026-10-08, consensus EPS -0.66 USD. Last quarter (2026-07-09) it missed with EPS -0.81 USD vs -0.73 USD est (-11%). It has beaten estimates in 4/8 recent quarters (50%). Trailing P/E -6.84.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does NRIX next report earnings?

Next earnings date2026-10-08
Consensus EPS estimate-0.66 USD
Revenue estimate0.02B

NRIX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-07-09-0.81 USD-0.73 USD-11%Miss
2026-04-08-0.79 USD-0.76 USD-3.9%Miss
2026-01-28-0.82 USD-0.84 USD+2.4%Beat
2025-10-09-1.03 USD-0.84 USD-22.6%Miss
2025-07-09-0.52 USD-0.71 USD+26.8%Beat
2025-04-08-0.67 USD-0.72 USD+6.9%Beat
2025-01-28-0.75 USD-0.67 USD-11.9%Miss
2024-10-11-0.67 USD-0.67 USD0%Beat

Beat rate: 4/8 (50%) over reported quarters with consensus data.

NRIX valuation and analyst view

Trailing P/E-6.84
Trailing EPS-3.0729 USD
Price / book6.51
Dividend yield0.00%
Market cap2.04B
Analyst consensusBuy (19 buy / 0 hold / 0 sell)
Avg price target33.75 USD

Related research pages

Frequently asked questions

When is Nurix Therapeutics (NRIX)'s next earnings date?

Nurix Therapeutics is next scheduled to report on 2026-10-08, with a consensus EPS estimate of -0.66 USD and revenue estimate of 0.02B.

Did NRIX beat earnings last quarter?

In its 2026-07-09 report, NRIX posted EPS of -0.81 USD versus a -0.73 USD estimate — a miss of 11%.

What is NRIX's earnings track record?

Over the last 8 reported quarters with consensus data, NRIX beat estimates 4 times (50%).

What is NRIX's current P/E ratio and EPS?

NRIX trades at a trailing P/E of -6.84 on trailing EPS of -3.072897088370347 USD.

What do analysts rate NRIX?

Analyst consensus is "Buy" across 19 ratings (0 strong buy, 19 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 33.75 USD.